Study Graphic

The Pfizer New Haven Clinical Research Unit is conducting a study of an investigational drug used to treat people with cachexia. Cachexia is weakness and wasting of the body due to a severe chronic illness such as cancer. This research study will be the first time the study drug will be given to people. Study drug and placebo (contains no active study drug) will be given by subcutaneous injection (SC – injected under the skin). If you are accepted in the study, you will be randomly assigned (like the flip of a coin) to receive a single dose of either the study drug or placebo.

You may be eligible if:

  • You are a healthy male or female (unable to bear children) 18-55 years of age.
  • You are able to meet all eligibility criteria.
  • You are able to comply with all study visits.

Study Number: C3651001

Be compensated for your time if you are enrolled in one of the below groups:

  • Groups 1 to 5: up to $5,575.00 for completion of the study
  • Group 6: up to $6,125.00 for completion of the study
  • Group 7: up to $6,775.00 for completion of the study

This study involves:

You will be in this study up to about 64, 85 or 113 days depending on your subject group.  This does not include the time between screening and dosing, which can be up to 28 days.

 This study involves:

  • 1 dosing period
  • 15 overnight stays
  • Up to 3, 4 or 5 follow up visits to the clinic depending on your subject group

Please review the Informed Consent Document: C3651001 revised ICD v29Aug2018

Please review more information about the study: C3651001 revised Guidelines Restrictions Dates v29Aug2018

For Japanese population: C3651001 revised Japanese ICD v10Jan2019